MX2007009466A - Anticuerpos monoclonales de anti-interferon alfa y metodos para su uso. - Google Patents
Anticuerpos monoclonales de anti-interferon alfa y metodos para su uso.Info
- Publication number
- MX2007009466A MX2007009466A MX2007009466A MX2007009466A MX2007009466A MX 2007009466 A MX2007009466 A MX 2007009466A MX 2007009466 A MX2007009466 A MX 2007009466A MX 2007009466 A MX2007009466 A MX 2007009466A MX 2007009466 A MX2007009466 A MX 2007009466A
- Authority
- MX
- Mexico
- Prior art keywords
- ifn
- bioactivity
- antibodies
- methods
- subtypes
- Prior art date
Links
- 238000000034 method Methods 0.000 title abstract 2
- 230000001064 anti-interferon Effects 0.000 title 1
- 102000004169 proteins and genes Human genes 0.000 abstract 3
- 108090000623 proteins and genes Proteins 0.000 abstract 3
- 208000030507 AIDS Diseases 0.000 abstract 1
- 208000009329 Graft vs Host Disease Diseases 0.000 abstract 1
- 102000006992 Interferon-alpha Human genes 0.000 abstract 1
- 108010047761 Interferon-alpha Proteins 0.000 abstract 1
- 208000007452 Plasmacytoma Diseases 0.000 abstract 1
- 201000004681 Psoriasis Diseases 0.000 abstract 1
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 abstract 1
- 230000004913 activation Effects 0.000 abstract 1
- 230000000840 anti-viral effect Effects 0.000 abstract 1
- 210000004027 cell Anatomy 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 208000035475 disorder Diseases 0.000 abstract 1
- 239000012634 fragment Substances 0.000 abstract 1
- 208000024908 graft versus host disease Diseases 0.000 abstract 1
- 210000004408 hybridoma Anatomy 0.000 abstract 1
- 206010025135 lupus erythematosus Diseases 0.000 abstract 1
- 238000005259 measurement Methods 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 230000001225 therapeutic effect Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/249—Interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Diabetes (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Virology (AREA)
- Biophysics (AREA)
- Oncology (AREA)
- Endocrinology (AREA)
- Dermatology (AREA)
- Communicable Diseases (AREA)
- Tropical Medicine & Parasitology (AREA)
- Mycology (AREA)
- AIDS & HIV (AREA)
- Transplantation (AREA)
- Emergency Medicine (AREA)
- Obesity (AREA)
- Microbiology (AREA)
- Hematology (AREA)
- Epidemiology (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US65223305P | 2005-02-10 | 2005-02-10 | |
| PCT/US2006/004643 WO2006086586A2 (en) | 2005-02-10 | 2006-02-09 | Anti-interferon alpha monoclonal antibodies and methods for use |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2007009466A true MX2007009466A (es) | 2007-12-07 |
Family
ID=36694481
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2007009466A MX2007009466A (es) | 2005-02-10 | 2006-02-09 | Anticuerpos monoclonales de anti-interferon alfa y metodos para su uso. |
Country Status (14)
| Country | Link |
|---|---|
| US (2) | US8080638B2 (enExample) |
| EP (1) | EP1851248B1 (enExample) |
| JP (2) | JP5837730B2 (enExample) |
| KR (1) | KR101363120B1 (enExample) |
| CN (1) | CN101155831B (enExample) |
| AU (1) | AU2006213800B2 (enExample) |
| BR (1) | BRPI0607490A2 (enExample) |
| CA (1) | CA2597265C (enExample) |
| IL (1) | IL184808A0 (enExample) |
| MX (1) | MX2007009466A (enExample) |
| NO (1) | NO343054B1 (enExample) |
| RU (1) | RU2431638C2 (enExample) |
| WO (1) | WO2006086586A2 (enExample) |
| ZA (1) | ZA200706425B (enExample) |
Families Citing this family (35)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NZ554065A (en) * | 2004-10-07 | 2010-12-24 | Univ Zuerich | Use of an anti-interferon-alpha antibody for prevention and treatment of psoriasis |
| CA2597265C (en) * | 2005-02-10 | 2015-03-24 | Baylor Research Institute | Anti-interferon alpha monoclonal antibodies and methods for use |
| US7888481B2 (en) | 2005-02-10 | 2011-02-15 | Baylor Research Institute | Anti-interferon alpha monoclonal antibodies and methods for use |
| WO2008021976A2 (en) * | 2006-08-09 | 2008-02-21 | Baylor Research Institute | Anti-interferon alpha monoclonal antibodies and methods for use |
| CN101678100A (zh) * | 2006-12-06 | 2010-03-24 | 米迪缪尼有限公司 | 治疗系统性红斑狼疮的方法 |
| WO2008070135A2 (en) * | 2006-12-06 | 2008-06-12 | Medimmune, Llc. | Methods of treating systemic lupus erythematosus |
| CA2674880A1 (en) | 2007-01-25 | 2008-07-31 | Universite Libre De Bruxelles | Method for evaluating the response of an individual to a treatment with a type i interferon (ifn) |
| AU2008232903B9 (en) * | 2007-03-30 | 2013-09-05 | Medimmune Llc | Antibodies with decreased deamidation profiles |
| CA2685147A1 (en) * | 2007-05-03 | 2008-11-13 | Medimmune, Llc | Auto-antibody markers of autoimmune disease |
| EP2014681A1 (en) | 2007-07-12 | 2009-01-14 | Pierre Fabre Medicament | Novel antibodies inhibiting c-met dimerization, and uses thereof |
| EP2254998B1 (en) | 2008-02-28 | 2015-12-23 | Argos Therapeutics, Inc. | Transient expression of immunomodulatory polypeptides for the prevention and treatment of autoimmune disease, allergy and transplant rejection |
| EP2279207B1 (en) | 2008-05-07 | 2015-09-09 | Argos Therapeutics, Inc. | Humanized antibodies against human interferon-alpha |
| KR101843915B1 (ko) * | 2008-08-14 | 2018-04-02 | 제넨테크, 인크. | 고유 단백질 대체 이온 교환 막 크로마토그래피를 이용한 오염물의 제거 방법 |
| CN101580546B (zh) * | 2009-06-04 | 2011-09-14 | 中国疾病预防控制中心病毒病预防控制所 | 人源抗人干扰素α抗体及其应用 |
| SG10201501803YA (en) | 2010-03-12 | 2015-05-28 | Immunogen Inc | Cd37-binding molecules and immunoconjugates thereof |
| EP2694105A4 (en) | 2011-04-01 | 2015-04-29 | Immunogen Inc | CD37 BINDING MOLECULES AND IMMUNOCONJUGATES THEREOF |
| AU2013204880B2 (en) * | 2011-04-26 | 2016-11-24 | Genentech, Inc. | Compositions and method for treating autoimmune diseases |
| CA2834203A1 (en) * | 2011-04-26 | 2012-11-01 | Genentech, Inc. | Compositions and method for treating autoimmune diseases |
| CN105358575B (zh) | 2013-03-15 | 2020-09-22 | 詹森生物科技公司 | 干扰素α和ω抗体拮抗剂 |
| EP4056591A1 (en) * | 2013-07-03 | 2022-09-14 | ImmunoQure AG | Human anti-ifn-alpha antibodies |
| CN106029874B (zh) * | 2013-12-16 | 2020-09-15 | 北卡罗来纳-查佩尔山大学 | 浆细胞样树突状细胞的耗竭 |
| EP3247725B1 (en) * | 2015-01-23 | 2020-07-01 | Sanofi | Anti-cd3 antibodies, anti-cd123 antibodies and bispecific antibodies specifically binding to cd3 and/or cd123 |
| JP6979877B2 (ja) | 2015-06-08 | 2021-12-15 | デビオファーム インターナショナル， エス． アー． | 抗ｃｄ３７イムノコンジュゲートおよび抗ｃｄ２０抗体の組み合わせ |
| CA2995243A1 (en) | 2015-08-28 | 2017-03-09 | Debiopharm International, S.A. | Antibodies and assays for detection of cd37 |
| KR102802736B1 (ko) * | 2016-03-10 | 2025-05-02 | 비엘라 바이오, 인크. | Ilt7 결합 분자 및 이의 사용 방법 |
| JP2020510608A (ja) | 2016-11-02 | 2020-04-09 | デビオファーム インターナショナル， エス． アー． | 抗ｃｄ３７イムノコンジュゲート療法を改善するための方法 |
| CN107858449A (zh) * | 2017-12-05 | 2018-03-30 | 安徽九川生物科技有限公司 | 一种犬干扰素α生物学活性检测方法 |
| CN118667812A (zh) | 2017-12-06 | 2024-09-20 | 艾维迪提生物科学公司 | 治疗肌萎缩和强直性肌营养不良的组合物和方法 |
| RU2694672C1 (ru) * | 2018-04-27 | 2019-07-16 | Открытое акционерное общество "Всероссийский научный Центр молекулярной диагностики и лечения" (ОАО ВНЦМДЛ) | Вариабельные домены лёгкой и тяжёлой цепи мышиного моноклонального антитела против интерферона альфа (IFN-α) человека, антигенсвязывающий фрагмент (Fab) против IFN-α человека, содержащий указанные домены |
| JP2021525735A (ja) | 2018-05-30 | 2021-09-27 | デビオファーム インターナショナル， エス． アー． | 抗ｃｄ３７免疫コンジュゲート投薬レジメン |
| JP2022527542A (ja) | 2019-04-04 | 2022-06-02 | ヤンセン バイオテツク，インコーポレーテツド | 抗ＩＦＮ－α／ω抗体の投与方法 |
| RU2748953C1 (ru) * | 2019-12-30 | 2021-06-02 | Федеральное государственное бюджетное учреждение науки институт биоорганической химии им. академиков М.М. Шемякина и Ю.А. Овчинникова Российской академии наук (ИБХ РАН) | Рекомбинантный Fab-scFv на основе нейтрализующего антитела против интерферона бета-1а человека и антитела против рецептора ErbB2 человека |
| RU2737466C1 (ru) * | 2019-12-30 | 2020-11-30 | Федеральное государственное бюджетное учреждение науки институт биоорганической химии им. академиков М.М. Шемякина и Ю.А. Овчинникова Российской академии наук (ИБХ РАН) | Гуманизированное нейтрализующее антитело к интерферону-бета человека |
| JP7748962B2 (ja) | 2020-03-27 | 2025-10-03 | アビディティー バイオサイエンシーズ，インク． | 筋ジストロフィーを処置するための組成物および方法 |
| CN119841955A (zh) * | 2023-12-19 | 2025-04-18 | 重庆艾生斯生物工程有限公司 | 一种抗MxA抗体或其功能性片段及其应用 |
Family Cites Families (44)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3001687C2 (de) | 1980-01-18 | 1981-09-17 | Kläger, Karlheinz, 8901 Neusäß | Verstellbare Düse an einem handbetätigten Flüssigkeitszerstäuber |
| US4423147A (en) | 1980-04-11 | 1983-12-27 | Secher David S | Monoclonal antibody to interferon-α |
| US4605394A (en) | 1982-12-03 | 1986-08-12 | Simon V. Skurkovich | Methods for the treatment of pathological conditions by removing interferon from the organism |
| US4362155A (en) | 1981-03-24 | 1982-12-07 | Skurkovich Simon V | Method and apparatus for the treatment of autoimmune and allergic diseases |
| US4824432A (en) | 1981-03-24 | 1989-04-25 | S.V.S. Laboratories, Inc. | Method for treating AIDS and other immune deficiencies and immune disorders |
| DE3211263A1 (de) | 1981-03-31 | 1983-01-27 | Otsuka Pharmaceutical Co. Ltd., Tokyo | Human-interferon verwandte peptide, antigene und antikoerper, sowie verfahren zu deren herstellung |
| EP0139676B1 (en) | 1983-02-04 | 1992-11-25 | Cytoclonal Pharmaceutics Inc. | Production and characterization of hybridoma antibodies directed specifically against common determinant(s) present among closely related, but distinct proteins |
| GB2148299B (en) | 1983-09-01 | 1988-01-06 | Hybritech Inc | Antibody compositions of therapeutic agents having an extended serum half-life |
| FR2560212B1 (fr) | 1984-02-24 | 1989-12-29 | Unicet | Anticorps monoclonaux contre l'interferon a2 et hybridomes produisant de tels anticorps |
| AU2844889A (en) | 1988-01-22 | 1989-07-27 | Collagen Corporation | Method for suppressing the growth of normal and cancer cells |
| US5889151A (en) | 1989-10-20 | 1999-03-30 | Societe Leb-Tech | Purified human alpha interferon receptor |
| WO1992018626A1 (fr) | 1991-04-17 | 1992-10-29 | Laboratoire Europeen De Biotechnologie | POLYPEPTIDES HYDROSOLUBLES AYANT UNE HAUTE AFFINITE POUR LES INTERFERONS α ET $g(b) |
| WO1993004699A1 (en) | 1991-08-30 | 1993-03-18 | Genentech, Inc. | Therapeutic method for iddm |
| KR100223255B1 (ko) | 1992-02-10 | 1999-10-15 | 더글라스 테스타 | 개량된 알파 인터페론 조성물 및 인간 말초혈 백혈구로 부터의 제조 방법 |
| EP0563487A1 (en) | 1992-03-31 | 1993-10-06 | Laboratoire Europeen De Biotechnologie S.A. | Monoclonal antibodies against the interferon receptor, with neutralizing activity against type I interferon |
| US5821078A (en) | 1992-09-03 | 1998-10-13 | Yeda Research And Development Co. Ltd. | Nucleic acid encoding interferon-α/β binding protein |
| US5888511A (en) | 1993-02-26 | 1999-03-30 | Advanced Biotherapy Concepts, Inc. | Treatment of autoimmune diseases, including AIDS |
| US5780027A (en) | 1995-07-14 | 1998-07-14 | Meiogen Biotechnology Corporation | Methods of treatment of down syndrome by interferon antagonists |
| IL118096A0 (en) | 1996-05-01 | 1996-09-12 | Yeda Res & Dev | Antibodies against interferon alpha/beta receptor |
| US6713609B1 (en) | 1996-07-16 | 2004-03-30 | Genentech, Inc. | Monoclonal antibodies to type I interferon receptor |
| WO1998006431A2 (en) | 1996-08-16 | 1998-02-19 | Osther Kurt B | Method for treating diabetes |
| US5804955A (en) * | 1996-10-30 | 1998-09-08 | Cherry Semiconductor Corporation | Low voltage current limit circuit with temperature insensitive foldback network |
| US20030018174A1 (en) | 1997-10-06 | 2003-01-23 | Genentech, Inc. | Monoclonal antibodies to IFNAR2 |
| US6331396B1 (en) | 1998-09-23 | 2001-12-18 | The Cleveland Clinic Foundation | Arrays for identifying agents which mimic or inhibit the activity of interferons |
| AUPP670698A0 (en) | 1998-10-23 | 1998-11-19 | Monash University | A method of regulation |
| KR20000034847A (ko) | 1998-11-17 | 2000-06-26 | 성재갑 | 인간 4-1비비 분자에 대한 인간화 항체 및 이를 포함하는 약학조성물 |
| JP5007007B2 (ja) | 1999-11-15 | 2012-08-22 | ミルテニイ バイオテック ゲゼルシャフト ミット ベシュレンクテル ハフツング | 樹状細胞に特異的な抗原結合フラグメント、その組成物および使用方法、それによって認識される抗原およびそれによって得られる細胞 |
| GB0001712D0 (en) | 2000-01-25 | 2000-03-15 | Pharma Pacific Pty Ltd | Therapeutic peptides |
| GB0001710D0 (en) | 2000-01-25 | 2000-03-15 | Pharma Pacific Pty Ltd | Therapeutic treatment |
| US6846486B1 (en) | 2000-02-24 | 2005-01-25 | Advanced Biotherapy Concepts, Inc. | Method of treating allergy by administering an anti-histamine antibody |
| WO2002024874A2 (en) | 2000-09-21 | 2002-03-28 | Schering Corporation | Methods for preparing interferon producing dentitric cells |
| EP2236156A3 (en) | 2001-01-09 | 2011-01-05 | Baylor Research Institute | Methods for treating and diagnosing Psoriasis |
| US7087726B2 (en) | 2001-02-22 | 2006-08-08 | Genentech, Inc. | Anti-interferon-α antibodies |
| FR2822845B1 (fr) | 2001-03-30 | 2003-12-12 | Genodyssee | Nouveaux polynucleotides comportant des polymorphismes de type snp fonctionnels dans la sequence nucleotidique du gene ifn-alpha-21 ainsi que de nouveaux polypeptides codes par ces polynucleotides et leurs utilisations therapeutiques |
| AU2003203079B9 (en) | 2002-02-04 | 2009-01-15 | Oncothyreon Inc. | Immunostimulatory, covalently lipidated oligonucleotides |
| AU2002368062A1 (en) * | 2002-06-26 | 2004-01-19 | Imclone Systems Incorporated | Bispecific antibodies that bind to vegf receptors |
| EA013677B1 (ru) | 2002-11-15 | 2010-06-30 | Генмаб А/С | Человеческие моноклональные антитела против cd25 и их применение |
| MXPA05011406A (es) | 2003-04-23 | 2005-12-12 | Medarex Inc | Anticuerpos humanizados para el receptor-1 de interferon alfa (ifnar-1). |
| DK1711207T3 (da) | 2003-12-10 | 2013-03-11 | Medarex Inc | Interferon-alpha-antistoffer og anvendelse heraf |
| NZ554065A (en) | 2004-10-07 | 2010-12-24 | Univ Zuerich | Use of an anti-interferon-alpha antibody for prevention and treatment of psoriasis |
| WO2008021976A2 (en) | 2006-08-09 | 2008-02-21 | Baylor Research Institute | Anti-interferon alpha monoclonal antibodies and methods for use |
| CA2597265C (en) | 2005-02-10 | 2015-03-24 | Baylor Research Institute | Anti-interferon alpha monoclonal antibodies and methods for use |
| US7888481B2 (en) | 2005-02-10 | 2011-02-15 | Baylor Research Institute | Anti-interferon alpha monoclonal antibodies and methods for use |
| EP2279207B1 (en) | 2008-05-07 | 2015-09-09 | Argos Therapeutics, Inc. | Humanized antibodies against human interferon-alpha |
-
2006
- 2006-02-09 CA CA2597265A patent/CA2597265C/en active Active
- 2006-02-09 BR BRPI0607490-1A patent/BRPI0607490A2/pt not_active Application Discontinuation
- 2006-02-09 MX MX2007009466A patent/MX2007009466A/es active IP Right Grant
- 2006-02-09 AU AU2006213800A patent/AU2006213800B2/en not_active Ceased
- 2006-02-09 CN CN200680011269.3A patent/CN101155831B/zh not_active Expired - Fee Related
- 2006-02-09 JP JP2007555223A patent/JP5837730B2/ja not_active Expired - Fee Related
- 2006-02-09 RU RU2007133608/10A patent/RU2431638C2/ru active
- 2006-02-09 US US11/883,961 patent/US8080638B2/en active Active
- 2006-02-09 WO PCT/US2006/004643 patent/WO2006086586A2/en not_active Ceased
- 2006-02-09 EP EP06734693.2A patent/EP1851248B1/en active Active
- 2006-02-09 KR KR1020077020583A patent/KR101363120B1/ko not_active Expired - Fee Related
-
2007
- 2007-07-24 IL IL184808A patent/IL184808A0/en active IP Right Grant
- 2007-08-01 ZA ZA2007/06425A patent/ZA200706425B/en unknown
- 2007-09-06 NO NO20074512A patent/NO343054B1/no unknown
-
2011
- 2011-10-04 US US13/252,335 patent/US8333965B2/en not_active Expired - Fee Related
-
2014
- 2014-02-17 JP JP2014027929A patent/JP2014111644A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| CN101155831B (zh) | 2015-08-19 |
| RU2431638C2 (ru) | 2011-10-20 |
| US8333965B2 (en) | 2012-12-18 |
| IL184808A0 (en) | 2007-12-03 |
| US20120020963A1 (en) | 2012-01-26 |
| NO343054B1 (no) | 2018-10-22 |
| AU2006213800B2 (en) | 2012-02-09 |
| NO20074512L (no) | 2007-10-31 |
| KR20070107753A (ko) | 2007-11-07 |
| WO2006086586A3 (en) | 2006-10-12 |
| JP5837730B2 (ja) | 2015-12-24 |
| CA2597265A1 (en) | 2006-08-17 |
| AU2006213800A1 (en) | 2006-08-17 |
| CA2597265C (en) | 2015-03-24 |
| EP1851248B1 (en) | 2016-08-10 |
| BRPI0607490A2 (pt) | 2009-09-08 |
| EP1851248A2 (en) | 2007-11-07 |
| RU2007133608A (ru) | 2009-03-20 |
| JP2008529529A (ja) | 2008-08-07 |
| WO2006086586A2 (en) | 2006-08-17 |
| JP2014111644A (ja) | 2014-06-19 |
| CN101155831A (zh) | 2008-04-02 |
| KR101363120B1 (ko) | 2014-02-13 |
| US8080638B2 (en) | 2011-12-20 |
| ZA200706425B (en) | 2014-07-30 |
| US20080160030A1 (en) | 2008-07-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2007009466A (es) | Anticuerpos monoclonales de anti-interferon alfa y metodos para su uso. | |
| WO2008021976A3 (en) | Anti-interferon alpha monoclonal antibodies and methods for use | |
| De Souza et al. | SH2 domains from suppressor of cytokine signaling-3 and protein tyrosine phosphatase SHP-2 have similar binding specificities | |
| WO2005059106A3 (en) | Interferon alpha antibodies and their uses | |
| Proost et al. | Citrullination of CXCL8 by peptidylarginine deiminase alters receptor usage, prevents proteolysis, and dampens tissue inflammation | |
| US20180334488A1 (en) | Targeting of cytokine antagonists | |
| Mazzei et al. | Purification and characterization of a 26‐kDa competitive inhibitor of interleukin 1 | |
| DK1765860T3 (da) | Ny-ESO-T.cellereceptor med höj affinitet | |
| CY1108689T1 (el) | Ολιγοπεπτιδια για την ελαττωση αυξημενης συγκεντρωσεως της ουριας στο αιμα | |
| IL171356A (en) | Anti-interferon receptor antibody for treatment of inflammatory bowel disease | |
| RU2014122609A (ru) | Модифицированная константная область антитела | |
| WO2006002177A3 (en) | Interferon alpha receptor 1 antibodies and their uses | |
| WO2008060813A3 (en) | High affinity antibody antagonists of interleukin-13 receptor alpha 1 | |
| BRPI0413119A (pt) | uso de anticorpos com adcc otimizada para tratar pacientes debilitados | |
| DK1761553T3 (da) | MHC molecule-binding tumor-associated peptides | |
| SG163548A1 (en) | Methods and compositions with enhanced therapeutic activity | |
| ATE306498T1 (de) | Von zellen präsentierte peptide | |
| WO2004080957A3 (en) | Use of adnf polypeptides for treating anxiety and depression | |
| Chew et al. | Potential combinatorial effects of recombinant atypical chemokine receptors in breast cancer cell invasion: a research perspective | |
| ATE520025T1 (de) | Test für morbus-parkinson-therapeutika | |
| ATE415421T1 (de) | Deamidiertes interferon-beta | |
| ATE496121T1 (de) | Lactobacillus fermentum n-desoxyribosyl- transferasen und deren verwendung zur enzymatischen synthese von 2',3'- didesoxynucleosiden und 2',3'-didehydro-2',3'- didesoxynucleosiden | |
| Cavicchioni et al. | Oligomeric formylpeptide activity on human neutrophils | |
| Michiels et al. | The soluble extracellular portion of the human interferon-γ receptor is a valid substitute for evaluating binding characteristics and for neutralizing the biological activity of this cytokine | |
| Nesbitt et al. | Collagen binding molecules at the osteoclast plasma membrane |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant or registration |